Literature DB >> 9927583

Complementarity between 3' terminal nucleotides of tRNA and primer binding site is a major determinant for selection of the tRNA primer used for initiation of HIV-1 reverse transcription.

Q Yu1, C D Morrow.   

Abstract

The initiation of reverse transcription of human immunodeficiency virus type 1 (HIV-1) exclusively utilizes tRNALys,3 as a primer. Previous studies have shown that HIV-1 could use alternative tRNAs, such as tRNAIle or tRNAHis, to initiate reverse transcription only if the primer binding site (PBS) was made complementary to the 3' terminal 18 nucleotides of the cognate tRNA. However, upon in vitro culture, the viruses with a PBS complementary to the alternative tRNAs rapidly reverted to generate a PBS complementary to tRNALys,3. To investigate the process of reversion, we have constructed defective proviral genomes that contain a PBS complementary to tRNAIle or tRNAHis. The genomes contain the gene for xanthine-guanosine phosphoribosyl transferase (gpt) in place of env. Cotransfection of these proviral genomes with a plasmid-encoding vesicular stomatitis virus G protein (VSV-G) results in viruses that undergo a single round of HIV-1 infection; successful infections are scored as cells resistant to the drug mycophenolic acid. Using this single-round infection system, we demonstrated that HIV-1 with a PBS complementary to tRNAIle or tRNAHis is three- to fivefold less efficient in replication as measured by production of drug-resistant cell colonies compared to the wild-type virus. These viruses predominantly used the cognate tRNA as primer in their initial round of replication, although we did obtain a single cell colony in which the PBS was complementary to tRNALys,3. Using an HIV-1 provirus with a PBS complementary to yeast tRNAPhe, we established a single-round infection system in which the infectivity of this mutant HIV-1 relies on transfected yeast tRNAPhe. The results of our studies suggest that the mechanism for selection of the tRNA primer for initiation of reverse transcription relies primarily on the complementarity between the tRNA primerthe PBS. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9927583     DOI: 10.1006/viro.1998.9542

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  7 in total

1.  Selection of functional tRNA primers and primer binding site sequences from a retroviral combinatorial library: identification of new functional tRNA primers in murine leukemia virus replication.

Authors:  A H Lund; M Duch; F S Pedersen
Journal:  Nucleic Acids Res       Date:  2000-02-01       Impact factor: 16.971

2.  Essential regions of the tRNA primer required for HIV-1 infectivity.

Authors:  Q Yu; C D Morrow
Journal:  Nucleic Acids Res       Date:  2000-12-01       Impact factor: 16.971

3.  Selection of retroviral reverse transcription primer is coordinated with tRNA biogenesis.

Authors:  Nathan J Kelly; Matthew T Palmer; Casey D Morrow
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

4.  Identification of critical elements in the tRNA acceptor stem and T(Psi)C loop necessary for human immunodeficiency virus type 1 infectivity.

Authors:  Q Yu; C D Morrow
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

5.  Transfer of primer binding site-mutated simian immunodeficiency virus vectors by genetically engineered artificial and hybrid tRNA-like primers.

Authors:  A C Hansen; T Grunwald; A H Lund; A Schmitz; M Duch; K Uberla; F S Pedersen
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

6.  Structural elements of the tRNA TPsiC loop critical for nucleocytoplasmic transport are important for human immunodeficiency virus type 1 primer selection.

Authors:  Nathan J Kelly; Casey D Morrow
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

Review 7.  Avoiding Drug Resistance in HIV Reverse Transcriptase.

Authors:  Maria E Cilento; Karen A Kirby; Stefan G Sarafianos
Journal:  Chem Rev       Date:  2021-01-28       Impact factor: 60.622

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.